- Home
- ALLY vs MDGL Comparison
ALLY vs MDGL Comparison
Compare ALLY & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALLY | MDGL |
|---|---|---|
| Founded | 1919 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 12.8B |
| IPO Year | 2011 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ALLY | MDGL |
|---|---|---|
| Price | $41.83 | $546.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | $54.42 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 2.5M | 221.6K |
| Earning Date | 04-17-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | ★ 31.67 | N/A |
| EPS | ★ 2.11 | N/A |
| Revenue | ★ $7,914,000,000.00 | $180,133,000.00 |
| Revenue This Year | $24.30 | $58.39 |
| Revenue Next Year | $4.31 | $48.55 |
| P/E Ratio | $20.04 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.92 | $393.61 |
| 52 Week High | $47.29 | $615.00 |
Technical Indicators
Market Signals| Indicator | ALLY | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 56.79 |
| Support Level | $41.00 | $499.26 |
| Resistance Level | $42.30 | $566.70 |
| Average True Range (ATR) | 0.82 | 17.10 |
| MACD | 0.03 | 1.58 |
| Stochastic Oscillator | 25.35 | 88.70 |
Price Performance
Historical ComparisonAbout ALLY Ally Financial Inc.
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.